<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02525237</url>
  </required_header>
  <id_info>
    <org_study_id>Ahead-G316</org_study_id>
    <nct_id>NCT02525237</nct_id>
  </id_info>
  <brief_title>Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer</brief_title>
  <official_title>Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingdao Municipal Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Qingdao Municipal Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Apatinib combined with
      S-1 as first-line therapy for patients with advanced gastric or gastroesophageal junction
      adenocarcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Event driven, an expected average of 8 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety will be assessed by incidence of adverse events</measure>
    <time_frame>An expected average of 8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>An expected average of 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>An expected average of 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Event driven, an expected average of 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>An expected average of 24 months</time_frame>
    <description>Quality of life of patient will be measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 [EORTC QLQ-C30].</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib plus S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib (500 mg qd p.o.) concomitantly with S-1 (40 mg/m2 qd days 1-14 q3w p.o.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity</description>
    <arm_group_label>Apatinib plus S-1</arm_group_label>
    <other_name>ATAN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>S-1 (40 mg/m2 qd days 1-14 q3w p.o.) until disease progression or intolerable toxicity</description>
    <arm_group_label>Apatinib plus S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients, aged ≥18 years;

          2. Histologically confirmed adenocarcinoma of the stomach with inoperable locally
             advanced or recurrent and/or metastatic disease;

          3. Measurable disease, according to the Response Evaluation Criteria in Solid Tumors
             (RECIST v1.1);

          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3;

          5. No previous chemotherapy for advanced/metastatic disease 1) Prior adjuvant/neoadjuvant
             therapy is allowed if at least 6 months has elapsed between completion of
             adjuvant/neoadjuvant therapy and enrolment into the study); 2) No previous targeted
             therapy; 3) For patients who can't tolerate first-line chemotherapy or refuse to
             accept chemotherapy, if they request to participate in this study, may receive
             apatinib monotherapy after consultation with the principal investigator in
             consideration of ethics.

          6. Hematological, Biochemical and Organ Functions: HB ≥ 80 g/L, ANC ≥ 1.5×109/L, PLT ≥
             80×109/L, BIL &lt; 1.5×ULN, ALT or AST &lt; 2.5×ULN (or &lt; 5×ULN in patients with liver
             metastases), Serum Cr ≤ 1×ULN, Cr clearance ≥ 50 mL/min;

          7. Life expectancy of more than 3 months;

          8. Duration from operation is more than 4 weeks;

          9. For women of child-bearing age, the pregnancy test results (serum or urine) within 7
             days before enrolment must be negative. They will take appropriate methods for
             contraception during the study until the 8th week post the last administration of
             study drug. For men (previous surgical sterilization accepted), will take appropriate
             methods for contraception during the study until the 8th week post the last
             administration of study drug.

         10. Signed informed consent.

        Exclusion Criteria:

          1. Patients with poor-controlled arterial hypertension (systolic blood pressure &gt; 140
             mmHg or diastolic blood pressure &gt; 90 mm Hg) despite standard medical management;
             Coronary heart disease, arrhythmia (including QT interval prolongation, for man &gt; 450
             ms, for woman &gt; 470 ms), and cardiac dysfunction greater than Class II;

          2. Factors affecting the oral medication, such as inability to swallow, chronic diarrhea
             and intestinal obstruction;

          3. Patients with a clear tendency of gastrointestinal bleeding;

          4. Abnormal coagulation function (INR &gt; 1.5×ULN, APTT &gt; 1.5×ULN), with tendency of bleed;

          5. Pregnant or lactating women;

          6. Other conditions regimented at investigators' discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaochun Zhang, MD, PhD</last_name>
    <phone>+86 0532 88905767</phone>
    <email>zxc96701@126.com</email>
  </overall_contact>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2015</study_first_submitted>
  <study_first_submitted_qc>August 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2015</study_first_posted>
  <last_update_submitted>August 14, 2015</last_update_submitted>
  <last_update_submitted_qc>August 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qingdao Municipal Hospital</investigator_affiliation>
    <investigator_full_name>Xiaochun Zhang</investigator_full_name>
    <investigator_title>Chairman</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

